Potential Impacts of the EMA-HMA Join Statement Supporting Biosimilar Interchangeability in Biosimilar Access in the EU

Author(s)

Ribeiro A1, Sazakli EA2, O'Hara M3, Martin De Bustamante M3, Vandeyar A3
1Trinity Life Sciences, Matosinhos, 13, Portugal, 2Trinity Life Sciences, New York, NY, USA, 3Trinity Life Sciences, Waltham, MA, USA

OBJECTIVES: On April 21, 2023, the EMA-HMA published a statement on the scientific rationale supporting the interchangeability of biosimilars, by recognizing their clinical equivalence to originators based on almost two decades of Real-World Evidence. Since the implementation of switching and substitution policies without prescriber’s consent falls outside the EMA’s jurisdiction, this research’s aims to explore payer reactions to this endorsement and potential impacts in biosimilar utilization policies in five key European countries.

METHODS: We reviewed EMA statements on biosimilar interchangeability, alongside country-specific guidance on biosimilar use across France, Italy, Germany, Spain and the U.K.. Primary research with payers will assess perceptions on the joint statement and the downstream impact on biosimilar access.

RESULTS: Policies of five key European countries have been evolving towards a more conducive environment for biosimilars. For example, the U.K.’s MHRA has discontinued the requirement for biosimilars to undergo confirmatory efficacy trials as a licensing condition in 2021, and most key European countries currently allow switching to biosimilars. However, in France, Italy and the U.K. this practice is still physician-driven (no mandatory INN prescribing), and automatic pharmacy substitution is only permitted in France (with restrictions). Alongside market-specific movements to further enable biosimilar adoption, we anticipate this joint statement will give EU payers a significant incentive to implement automatic substitution policies, although some backlash from healthcare providers is still expected.

CONCLUSIONS: Although payers do not feel comfortable enforcing automatic biosimilar substitution as of yet, the recognition of biosimilar interchangeability by the EMA could be sufficient to alleviate any remaining payer and healthcare provider concerns surrounding bioequivalence, drive future policy changes and increase patient access to biosimilars.

Conference/Value in Health Info

2023-11, ISPOR Europe 2023, Copenhagen, Denmark

Value in Health, Volume 26, Issue 11, S2 (December 2023)

Code

HPR103

Topic

Health Policy & Regulatory

Topic Subcategory

Approval & Labeling, Health Disparities & Equity, Public Spending & National Health Expenditures, Reimbursement & Access Policy

Disease

Biologics & Biosimilars, No Additional Disease & Conditions/Specialized Treatment Areas

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×